Kornimate/medical-research-clean huggingface dataset:
fascia iliaca block for anesthesia in lower limb thromboembolectomy

Conditions: Chronic Lower Limb Ischemia

Summary: the fascia iliaca block (fib) is an anterior approach to block the lumbar plexus. it disturbed mainly to the anterior region of the thigh by blocking the femoral nerve (lfc) and the lateral femoral cutaneous nerve. moreover, fib may possibly be extended to the obturator, ilioinguinal, genitofemoral, lateral cutaneous nerve of the thigh and over the psoas muscle but, rarely reaches the lumbar plexus. the fascia iliaca compartment could be detected by bony landmarks palpation and the loss of resistance technique. feeling two tactile ''pops'' due to loss of resistance occurred during the needle passage through the fascia lata and the fascia iliaca. ultrasound (us) guidance of fib will increase the success rate and the efficacy of sensory blockade by decreasing the needed local anesthetic amount.

this study was conducted to demonstrate the success incidence (to evaluate the efficacy) of preoperative 0.25% bupivacaine fib as a sole anesthetic technique in thromboembolectomy of unilateral chronic lower limb ischemia compared to neuraxial anesthesiaas a primary goal. intraoperative hemodynamics variation, postoperative pain score, total analgesic rescue requests and the total amount of systemic rescue analgesia used in the first postoperative day in addition to any detected postoperative complications were secondary goals. the hypothesis is that; fib will provide adequate anesthesia as neuraxial anesthesia.

Eligibility criteria:
inclusion criteria: * asa physical status i or ii. exclusion criteria: * patients with previous same lower limb surgery * neuromuscular disease * severe cardiovascular disease * any contraindications to regional anesthesia * patient refusal * coagulation abnormality * known allergy to local anesthetics * infection at the injection site
ocular examination at cell resolution with optical transmissiontomography

Conditions: Glaucoma Associated With Other Ocular Disorders

Summary: understanding the pathogenesis of eye diseases has benefited greatly from recent advances in ophthalmic imaging. however, current clinical imaging systems, such as optical coherence tomography (oct), are limited in terms of resolution, acquisition speed or access to certain eye functions. our team has participated in the development of a new generation of imaging technology known as optical transmission tomography (ott), which enables imaging of the anterior parts of the eye with high cellular resolution, a wide field of view and reduced examination delay.

for healthy subjects: an imaging examination using each system (ott + oct + specular microscopy) will be carried out twice, at an interval of two (2) years (inclusion visit + visit at 24 months). several imaging images will be taken by two different operators during these sessions. for patients: an imaging examination using each system (ott + oct + specular microscopy) will be carried out by two different operators, and several imaging images will be taken. these examinations will be carried out at the inclusion visit and at the following visits according to the disease assessment schedule, lasting up to a maximum of 4 years.

Eligibility criteria:
inclusion criteria: for patients: * 200 subjects aged 18 to 80 years; * male or female; * with an ocular disease affecting the cornea, ocular surface, lens (cataract) or glaucoma, or requiring refractive surgery or post-refractive surgery follow-up; * are covered by the french assurance maladie; * have signed an express, free and informed consent form. for healthy volunteers: * 100 subjects aged 18 to 80 years; * male or female; * healthy subjects with no known pathology directly or indirectly affecting ocular structures; * covered by the french assurance maladie. * having signed an express, free and informed consent form. exclusion criteria: for all participants: * inability to hold a still position on a standard ophthalmic chin rest; * conjunctivitis or other contagious contact disease in active phase; * having an implanted pacemaker or other electronic medical device; * having a predisposition to iridocorneal angle closure; * vulnerable persons or persons under legal protection (pregnant or breast-feeding women; persons under guardianship,
examination of vitiligo skin samples before and after uvb treatment

Conditions: Vitiligo

Summary: the keratinocytes of lesional skin of vitiligo compared to normal and perilesional skin will differentially express genes correlating with melanocyte death. narrow band uvb should then hopefully reverse the pattern of gene expression back toward normal.

vitiligo is a disease caused by the disappearance of melanocytes in the epidermis. the pathogenesis of vitiligo is multifactorial. theories include autoimmunity, neural, apoptosis and cytotoxicity. the medical treatments for vitiligo are marginal with a 40-60% response rate which does not guarantee full repigmentation. understanding the pathogenesis of vitiligo will allow better targets for treatment. previous analysis of skin biopsies have found several of the changes in gene expression occurred in immune regulation, dna replication and repair, oncogenes, signal transducers and transcription factors. these results give us insight as to what happens in lesional vs nonlesional skin which contains the epidermis, dermis, fat, blood vessels and immune cells. we have the technology today to study specific cell populations from tissue by the use of laser capture microdissection. we propose to use this technique to study the keratinocyte population in vitiligo skin because past evidence suggests that they may play a role. in addition, the role keratinocytes in vitiligo may be important for treatment as this would be the ideal target for therapy. keratinocytes have been studied in vitiligo. the aim of the study is to isolate keratinocytes from normal skin, perilesional and lesional skin in vitiligo patients by laser capture microdissection and characterize their gene expression profile by gene microarray analysis and to compare keratinocyte gene expression in normal, perilesional and lesional vitiligo skin before and after narrow band uvb treatment.

Eligibility criteria:
inclusion criteria: patients should have non-treated symmetrically active vitiligo for 3 months. exclusion criteria: less than 18 years old and older that 65, pregnant women, segmental or nonactive vitiligo, patients treated for vitiligo in past 3 month, patients on topical steroid medications, topical tacrolimus or elidel, patients receiving ultraviolet therapy including narrow band uvb, puva or tanning beds.

Keywords: keratinocyte
effect of apc and epo on the inflammatory response during sepsis

Conditions: Sepsis; Systemic Inflammation

Summary: an observational study to determine the effect of apc and epo in reducing the systemic inflammatory response during severe sepsis.

an observational study to determine the effect of apc and epo in reducing the systemic inflammatory response during severe sepsis. patients already prescribed either drug will be enrolled. the microcirculation of the sublingual vascular bed will be observed with a microscope to detect the alterations in the inflammatory response.

Eligibility criteria:
inclusion criteria: * patients in the icu in severe septic shock undergoing apc and/or epo treatment exclusion criteria: * any severe comorbid conditions

Keywords: systemic inflammation microvascular perfusion septic shock
efficacy of exercise methods in postmenopausal women: a clinical trial

Conditions: Post Menopausal Women

Summary: this study aims to evaluate the effectiveness of different exercise methods in improving health outcomes for postmenopausal women. as women go through menopause, they may experience changes such as decreased bone density, muscle weakness, and an increased risk of chronic diseases. exercise is known to be beneficial in reducing these risks, but the best approach remains unclear. in this clinical trial, participants will engage in structured exercise programs designed to improve bone health, strength, and overall well-being. the study will compare different types of exercises to determine which method provides the most benefits. by participating in this research, postmenopausal women can contribute to a better understanding of how exercise can enhance health during this stage of life. this study is safe, and all exercises are guided by professionals. the results will help healthcare providers recommend the most effective exercise strategies for postmenopausal women.


Eligibility criteria:
inclusion criteria: * being between 40-65 years of age having a body mass index (bmi) below 40 scoring 68 or above on the system usability scale having no orthopedic problems completing the informed consent form being within 5 years after a 12-month amenorrhea history exclusion criteria: * presence of visual impairments presence of musculoskeletal system disorders presence of cognitive impairments presence of joint range of motion limitations presence of severe cardiac problems participation in another program
p53 in differentiated thyroid cancer

Conditions: Thyroid Neoplasms

Summary: in clinical practise patients with negative radioiodine scan with positive tyhroglobulin is considered as radioiodine resistant or in another words in the process of dedifferentiation. the aim of the present study was to search a simple blood test that could lead to early identification of patients with dedifferentiation. in this respect, we investigate whether the serum level of anti-p53 antibody has the diagnostic value in the follow-up of patients with high levels of thyroglobulin (tg) and negative i-131 scan.

in the present study enrolled were 171 patients with mean age of 47.7±13.5 yrs (range; 16-80yrs) and 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0±9.8 yrs). 134 (78.4%) patients were female and 37 (21.6%) patients were male.

Eligibility criteria:
inclusion criteria: * patients who were diagnosed with dtc * treated with total and/or near-total thyroidectomy * referred for i-131 ablation therapy or low dose i-131 whole body scan (wbs) * between december 2010 and january 2013. exclusion criteria: * dose 131-i given in another hospital * radioiodine treatment more than one year after thyroidectomy.

Keywords: tumor suppressor protein p53, iodine radioisotopes
diabetic retinopathy screening in private practice

Conditions: Diabetic Retinopathy

Summary: introduction: diabetic mellitus (dm) is a prevalent disease in hong kong (hk) and diabetic retinopathy (dr) is one of the most common complications of dm. screening for dr is a cost-effective method to identify patients who are at risk of vision loss so that timely treatment can be provided to patients. in hong kong, the hospital authority has recently set up screening services (ramp) in the government outpatient clinics and all dm patients attending these clinics will be screened at least once every two years and some every six months, according to their individual risks. however, those diabetic patients who attend the private sector for their primary care may not have access to this service. aim: this study from the university of hong kong aims to determine the characteristics of a sustainable approach to setting up an effective and quality-controlled screening service for dr in the private primary care sector of hong kong and to estimate the potential benefit to be gained in terms of impact on avoidable vision loss, costs of care and potential for further development of this model in chronic disease care. methods:a screening centre is being set up and a randomised study carried out in which screening will be offered at three different fee levels to subjects recruited by their general practitioner (gp). the following data will be collected (a) willingness to attend screening at the different fee levels (b) screening findings in terms of dr and other eye diseases (c) risk factors and other characteristics of those screened and unscreened. the information will allow us to estimate the level of fee which best combines effectiveness with sustainability in the longer term.


Eligibility criteria:
inclusion criteria: * patients diagnosed to have diabetic mellitus * able to give informed consent exclusion criteria: * pregnant women

Keywords: diabetic retinopathy screening fee for screening private practice
pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the covid-19 pandemic

Conditions: COVID-19

Summary: the investigators aim to evaluate the efficacy of pre-exposure prophylaxis with hydroxychloroquine in healthcare workers with high-risk of sars-cov-2 infection.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * negative pcr and negative serology on day 0 * healthcare worker at any of the trial sites * female participants: negative for pregnancy test * willing to participate in the study * able to sign the informed consent form exclusion criteria: * age \<18 years * pregnancy or breastfeeding * ongoing antiviral or antiretroviral treatment or hiv positive * ongoing anti-inflammatory treatment (corticosteroids) * ongoing or previous (1 month) chloroquine or hydroxychloroquine treatment * confirmed case of sars-cov-2 infection (positive pcr) at day 0 * positive serology for sars-cov-1 infection at day 0 * impossibility of signing the informed consent form * rejection of participation * working less than 3 days a week in the hospital clinic of barcelona. * any contraindication for hydroxychloroquine treatment: * hydroxychloroquine hypersensitivity or 4-aminoquinoline hypersensitivity * retinopathy, visual field or visual acuity disturbances * qt prolongation, bradycardia (\<50bpm), ventricular tachycardia, other arrhythmias, as determined on day 0 ecg or medical history * potassium \ 5 upper normal limit, as determined on day 0 blood test * previous myocardial infarction * myasthenia gravis * porphyria * glomerular clearance \< 10ml/min * previous history of severe hypoglycaemia * ongoing treatment with antimalarials, antiarrhythmic, tricyclic antidepressants, selective serotonin reuptake inhibitors, natalizumab, quinolones, macrolides, agalsidase alfa and beta.

Keywords: prep hydroxychloroquine prophylaxis pre-exposure healthcare workers
immunogenicity and clinical efficacy of 20-valent pneumococcal conjugate vaccine (pcv20) in lymphoma survivors after treatment with anti-cd20 therapy

Conditions: Lymphoma

Summary: to compare the effects of a pneumococcal vaccine called pcv20 when given as a single dose versus a boosted regimen to patients who previously received anti-cd20 therapy as treatment for b cell lymphoma.

primary objectives: --compare the humoral responses in terms of difference in igg titers at 1 month from routine single dose pcv20 or a boosted pcv20 regimen in b cell lymphoma survivors who previously received treatment with anti-cd20 therapy. secondary objectives: * compare the humoral responses in terms of difference in igg titers at 3, 6 and12 from routine single dose pcv20 or a boosted pcv20 regimen in b cell lymphoma survivors who previously received treatment with anti-cd20 therapy. * estimate the rate of pneumonia (all bacterial pneumonia including pneumococcal pneumonia) within a year from routine single dose pcv20 or a boosted pcv20 regimen in lymphoma survivors who previously received treatment with anti-cd 20 therapy. * correlate humoral responses to development of bacterial pneumonia and pneumococcal pneumonia and with severity of this infection in lymphoma survivors within a year of vaccination.

Eligibility criteria:
inclusion criteria: 1. patients who have a history of non-hodgkin b-cell lymphoma and whose disease has been in remission for at least 1 year. 2. patients who received any anti-cd20 therapy at any time during their treatment for b-cell lymphoma. 3. patients who are at least 18 years of age. 4. patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf. exclusion criteria: 1. patients who have received cellular therapy, including chimeric antigen receptor t-cell therapy or any type of hematopoietic cell transplantation. 2. patients who have received pcv or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment. 3. patients who are unable to attend follow-up appointments at designated times at md anderson. 4. any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)
effect of somatropin on left ventricular mass in growth hormone deficient adult patients

Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency

Summary: this trial is conducted in europe. the aim of this trial is to assess the effect of somatropin (norditropin®) replacement therapy on the left ventricular mass of adult patients with a growth hormone deficiency.


Eligibility criteria:
inclusion criteria: * childhood or adult onset growth hormone deficiency (ghd) * ghd evidenced by two stimulation tests * duration of ghd at least 5 years * other hormone deficiencies associated with growth hormone deficiency exclusion criteria: * pregnancy or pregnancy desired during the suggested duration of the study * personal history of colonic polyp or family history of colonic polyposis * known insulin-dependent or non-insulin-dependent diabetes * cardiovascular disease, left ventricular hypertrophy from other aetiology, recent auricular or ventricular arrhythmia, history of vascularisation by aortocoronary bypass significative mitral or aortic valvular disease, preexcitation syndrome, auriculoventricular conduction delay, bradycardia-tachycardia syndrome, left ventricular mass interfering treatment * bmi (body mass index) at least 30 * growth hormone treatment during the 24 months prior to inclusion, history of treatment with extractive pituitary growth hormone, allergy or suspected allergy to somatropin therapy * patient who has participated in a different clinical study within the past two months * any condition which, in the opinion of the investigator or the scientific committee, may interfere with successful implementation of the study * notion of breast cancer for the mother or the sister
mucopolysaccharidosis type ii observational

Conditions: Mucopolysaccharidosis II

Summary: this is an observational study planned to document prospectively disease manifestation and neurocognitive course in pediatric patients with a clinical presentation consistent with neuronopathic ("severe") mps ii undergoing current standard of care and/or intrathecal elaprase® for their condition. some patients may be offered the opportunity to screen for a gene therapy study conducted by the same sponsor.

mps ii is a rare x-linked recessive genetic disease caused by mutations in the iduronate-2-sulfatase gene (ids). enzyme replacement therapy (ert) with recombinant idursulfase (elaprase®) is the only approved product for the treatment of hunter syndrome; however, ert as currently administered does not cross the blood brain barrier and is therefore unable to address the unmet need in mps ii patients with cns (neurocognition and behavior) involvement. this is an observational study to document prospectively disease manifestation and neurocognitive course in pediatric patients with a clinical presentation consistent with neuronopathic ("severe") mps ii undergoing current standard of care for their condition. approximately forty pediatric subjects who have severe mps ii will be enrolled. changes in neurodevelopmental parameters of cognitive, behavioral, and adaptive function over time will be the primary focus for a duration of 104 weeks.

Eligibility criteria:
inclusion criteria: 1. meets any of the following criteria: 1. has a clinical diagnosis of severe mps ii and has a documented mutation in ids, or 2. has a relative clinically diagnosed with severe mps ii who has the same ids mutation as the subject, or 3. has documented mutation(s) in ids that in the opinion of the investigator is known to result in a neuronopathic phenotype 2. has sufficient communication capacity to complete the required protocol testing patient's legal guardian must be willing and able to provide written, signed informed consent. exclusion criteria: 1. has had prior treatment with an aav-based gene therapy product 2. is currently participating in a clinical trial of an investigational product for the treatment of mps ii with the exception of it elaprase trials; no investigational product may be taken starting 30 days or 5 half-lives of the investigational product prior to signing the icf, whichever is longer

Keywords: mps ii gene therapy hunter
predictive factors for survival in aggressive meningiomas

Conditions: Meningioma; Meningioma Atypical; Anaplastic Meningioma

Summary: the investigators plan to collect clinical and molecular data, including ich, pcr, ngs and methylome, from patients operated on for grade 2 or grade 3 meningioma. the purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.


Eligibility criteria:
inclusion criteria: 1. patient operated for atypical (grade 2) meningioma; or 2. patient operated for anaplastic (grade 3) meningioma; 3. timeframe for surgery, 1999-2019 exclusion criteria 1) patient lost at follow-up
sore throat prevention following intubation

Conditions: Sore Throat

Summary: the aim of this interventional study is to find out the incidence of sore throat among intubated patients in jordan university hospital and to find out which is preventive and effective method to decrease sore throat;is it xylocaine gel on endotracheal cuff as lubricant versus dexamethasone 8 mg intravenously or both.

three groups were divided into: first group received xylocaine gel as endotracheal cuff lubricant,second group received dexamethasone 8 mg intravenously and third group received both( xylocaine and dexamethasone). the investigator compared between the three groups regarding sore throat in intubated patients and followed them up to 48 hours.

Eligibility criteria:
inclusion criteria: * asa 1-3. * elective vs emergency. * cuffed endo-tracheal tubes. * different types of surgery. exclusion criteria: * pregnant ladies. * icu patients. * \<15 years of age * laryngeal mask airway

Keywords: sore throat intubation xylocaine dexamethasone